annual CFF:
$612.46M+$341.09M(+125.69%)Summary
- As of today (August 3, 2025), VKTX annual cash flow from financing activities is $612.46 million, with the most recent change of +$341.09 million (+125.69%) on December 31, 2024.
- During the last 3 years, VKTX annual CFF has risen by +$605.58 million (+8802.09%).
- VKTX annual CFF is now at all-time high.
Performance
VKTX Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$507.00K+$158.00K(+45.27%)Summary
- As of today (August 3, 2025), VKTX quarterly cash flow from financing activities is $507.00 thousand, with the most recent change of +$158.00 thousand (+45.27%) on June 30, 2025.
- Over the past year, VKTX quarterly CFF has dropped by -$2.40 million (-82.55%).
- VKTX quarterly CFF is now -99.92% below its all-time high of $606.04 million, reached on March 31, 2024.
Performance
VKTX quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$4.38M-$2.40M(-35.39%)Summary
- As of today (August 3, 2025), VKTX TTM cash flow from financing activities is $4.38 million, with the most recent change of -$2.40 million (-35.39%) on June 30, 2025.
- Over the past year, VKTX TTM CFF has dropped by -$604.68 million (-99.28%).
- VKTX TTM CFF is now -99.50% below its all-time high of $873.23 million, reached on March 31, 2024.
Performance
VKTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
VKTX Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +125.7% | -82.5% | -99.3% |
| 3 y3 years | +8802.1% | +131.9% | +164.3% |
| 5 y5 years | +10000.0% | +21.9% | +483.0% |
VKTX Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | >+9999.0% | -99.9% | +131.9% | -99.5% | +164.3% |
| 5 y | 5-year | at high | >+9999.0% | -99.9% | +110.1% | -99.5% | +164.3% |
| alltime | all time | at high | >+9999.0% | -99.9% | +110.1% | -99.5% | +164.3% |
VKTX Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $507.00K(+45.3%) | $4.38M(-35.4%) |
| Mar 2025 | - | $349.00K(-65.1%) | $6.78M(-98.9%) |
| Dec 2024 | $612.46M(+125.7%) | $1.00M(-60.3%) | $612.46M(+0.1%) |
| Sep 2024 | - | $2.52M(-13.2%) | $611.65M(+0.4%) |
| Jun 2024 | - | $2.90M(-99.5%) | $609.06M(-30.3%) |
| Mar 2024 | - | $606.04M(>+9900.0%) | $873.23M(+221.8%) |
| Dec 2023 | $271.38M(+6418.8%) | $188.00K(-354.1%) | $271.38M(-3.7%) |
| Sep 2023 | - | -$74.00K(-100.0%) | $281.94M(-0.0%) |
| Jun 2023 | - | $267.08M(+6283.3%) | $282.02M(+2012.0%) |
| Mar 2023 | - | $4.18M(-61.1%) | $13.35M(+220.8%) |
| Dec 2022 | $4.16M(-39.5%) | $10.75M(>+9900.0%) | $4.16M(-163.7%) |
| Sep 2022 | - | $10.00K(-100.6%) | -$6.54M(-3.9%) |
| Jun 2022 | - | -$1.59M(-68.2%) | -$6.80M(+105.2%) |
| Mar 2022 | - | -$5.01M(<-9900.0%) | -$3.32M(-148.2%) |
| Dec 2021 | $6.88M(+624.2%) | $47.00K(-118.4%) | $6.88M(-5.7%) |
| Sep 2021 | - | -$256.00K(-113.5%) | $7.30M(-3.9%) |
| Jun 2021 | - | $1.90M(-63.4%) | $7.59M(+24.3%) |
| Mar 2021 | - | $5.19M(+1018.8%) | $6.11M(+542.9%) |
| Dec 2020 | $950.00K(+7.1%) | $464.00K(+1154.1%) | $950.00K(+32.9%) |
| Sep 2020 | - | $37.00K(-91.1%) | $715.00K(-4.8%) |
| Jun 2020 | - | $416.00K(+1160.6%) | $751.00K(+26.2%) |
| Mar 2020 | - | $33.00K(-85.6%) | $595.00K(-32.9%) |
| Dec 2019 | $887.00K | $229.00K(+213.7%) | $887.00K(-11.4%) |
| Sep 2019 | - | $73.00K(-71.9%) | $1.00M(-99.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2019 | - | $260.00K(-20.0%) | $168.41M(-29.3%) |
| Mar 2019 | - | $325.00K(-5.2%) | $238.30M(-20.6%) |
| Dec 2018 | $300.27M(+1240.5%) | $343.00K(-99.8%) | $300.27M(-4.6%) |
| Sep 2018 | - | $167.49M(+138.8%) | $314.69M(+112.2%) |
| Jun 2018 | - | $70.15M(+12.6%) | $148.32M(+80.5%) |
| Mar 2018 | - | $62.30M(+322.0%) | $82.17M(+266.8%) |
| Dec 2017 | $22.40M(+116.5%) | $14.76M(+1228.8%) | $22.40M(+158.2%) |
| Sep 2017 | - | $1.11M(-72.2%) | $8.68M(+13.1%) |
| Jun 2017 | - | $4.00M(+58.6%) | $7.67M(-40.7%) |
| Mar 2017 | - | $2.52M(+143.1%) | $12.93M(+24.9%) |
| Dec 2016 | $10.35M(-53.4%) | $1.04M(+858.7%) | $10.35M(+11.5%) |
| Sep 2016 | - | $108.30K(-98.8%) | $9.28M(+9.6%) |
| Jun 2016 | - | $9.26M(<-9900.0%) | $8.47M(-61.8%) |
| Mar 2016 | - | -$57.30K(+103.2%) | $22.17M(-0.2%) |
| Dec 2015 | $22.21M(+924.8%) | -$28.20K(-96.0%) | $22.21M(-1.9%) |
| Sep 2015 | - | -$704.70K(-103.1%) | $22.64M(-5.1%) |
| Jun 2015 | - | $22.96M(<-9900.0%) | $23.86M(+1010.0%) |
| Mar 2015 | - | -$17.90K(-104.4%) | $2.15M(-0.8%) |
| Dec 2014 | $2.17M(+740.5%) | $402.40K(-21.5%) | $2.17M(+22.8%) |
| Sep 2014 | - | $512.80K(-59.1%) | $1.77M(+40.9%) |
| Jun 2014 | - | $1.25M(>+9900.0%) | $1.25M(+481.5%) |
| Mar 2014 | - | $0.00(-100.0%) | $215.40K(0.0%) |
| Dec 2013 | $257.90K | - | - |
| Jun 2013 | - | $215.40K(>+9900.0%) | $215.40K(>+9900.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
FAQ
- What is Viking Therapeutics, Inc. annual cash flow from financing activities?
- What is the all time high annual CFF for Viking Therapeutics, Inc.?
- What is Viking Therapeutics, Inc. annual CFF year-on-year change?
- What is Viking Therapeutics, Inc. quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Viking Therapeutics, Inc.?
- What is Viking Therapeutics, Inc. quarterly CFF year-on-year change?
- What is Viking Therapeutics, Inc. TTM cash flow from financing activities?
- What is the all time high TTM CFF for Viking Therapeutics, Inc.?
- What is Viking Therapeutics, Inc. TTM CFF year-on-year change?
What is Viking Therapeutics, Inc. annual cash flow from financing activities?
The current annual CFF of VKTX is $612.46M
What is the all time high annual CFF for Viking Therapeutics, Inc.?
Viking Therapeutics, Inc. all-time high annual cash flow from financing activities is $612.46M
What is Viking Therapeutics, Inc. annual CFF year-on-year change?
Over the past year, VKTX annual cash flow from financing activities has changed by +$341.09M (+125.69%)
What is Viking Therapeutics, Inc. quarterly cash flow from financing activities?
The current quarterly CFF of VKTX is $507.00K
What is the all time high quarterly CFF for Viking Therapeutics, Inc.?
Viking Therapeutics, Inc. all-time high quarterly cash flow from financing activities is $606.04M
What is Viking Therapeutics, Inc. quarterly CFF year-on-year change?
Over the past year, VKTX quarterly cash flow from financing activities has changed by -$2.40M (-82.55%)
What is Viking Therapeutics, Inc. TTM cash flow from financing activities?
The current TTM CFF of VKTX is $4.38M
What is the all time high TTM CFF for Viking Therapeutics, Inc.?
Viking Therapeutics, Inc. all-time high TTM cash flow from financing activities is $873.23M
What is Viking Therapeutics, Inc. TTM CFF year-on-year change?
Over the past year, VKTX TTM cash flow from financing activities has changed by -$604.68M (-99.28%)